Abstract #0280
DSC-MRI Measures of Relative Cerebral Blood Volume (rCBV) as a Prognostic Marker for Progression-Free and Overall Survival in Recurrent Glioblastoma: Results from the ACRIN 6677/RTOG 0625 Multi-Center Trial
Kathleen M. Schmainda 1 , Zheng Zhang 2 , Jerrold Boxerman 3 , Melissa Prah 1 , Bradley Snyder 2 , Devyani Bedekar 4 , A Gregory Sorensen 5 , Mark R Gilbert 6 , and Daniel P Barboriak 7
1
Radiology, Medical College of Wisconsin,
Milwaukee, Wisconsin, United States,
2
Center
for Statistical Sciences, Brown University, Rhode
Island, United States,
3
Diagnostic
Imaging, Rhode Island Hospital, Rhode Island, United
States,
4
Medical
College of Wisconsin, Milwaukee, Wisconsin, United
States,
5
Massachusetts General Hospital,
Massachusetts, United States,
6
Neuro-Oncology,
University of Texas, Houston, Texas, United States,
7
Radiology,
Duke University, Durham, North Carolina, United States
RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase
II trial of bevacizumab with irinotecan or temozolomide
in recurrent glioblastoma (GBM). In this study of 23
patients the percent changes in both normalized and
standardized rCBV, derived from DSC-MRI, are predictive
of progression free survival (PFS) and overall survival
(OS) when measured at 2 and 16 weeks following treatment
initiation.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
